The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients

  title={The absence of early diarrhea with atropine premedication during irinotecan therapy in metastatic colorectal patients},
  author={Perran Fulden Yumuk and S Z Aydin and Faysal Dane and Mahmut Gumus and Meltem Ekenel and Mehmet Aliustaoğlu and Ayla Yavuz Karamanoğlu and Meriç Sengoz and Serdar Turhal},
  journal={International Journal of Colorectal Disease},
Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome.
Lack of difference in the incidence of cholinergic syndrome observed in irinotecan-treated patients suggests atropine-diphenoxylate and hyoscyamine may both be effective prophylactic options.
Muscarinic Receptors Associated with Cancer
The correlation between epidermal growth factor receptors and cholinergic muscarinic receptors, the survival differences adjusted by the stage clinical factor, and the association between gene expression and immune infiltration level in breast, lung, stomach, colon, liver, prostate, and glioblastoma human cancers are studied.
In vitro metabolic biomodulation of irinotecan to increase potency and reduce dose-limiting toxicity by inhibition of SN-38 glucuronide formation
Abstract Objectives Colorectal cancer continues to have one of the highest incidents of occurrence with a rising rate of diagnosis among people under the age of 50. Chemotherapy with irinotecan
Drug-induced diarrhea associated with antineoplastic drugs
Scientific literature data is analyzed on the prevalence, pathophysiological mechanisms and risk factors for the development of diarrhea associated with the intake of anticancer drugs, as well as its prevention and treatment.
Xiao-Chai-Hu-Tang (XCHT) Intervening Irinotecan's Disposition: The Potential of XCHT in Alleviating Irinotecan-Induced Diarrhea.
XCHT significantly decreased the exposure of SN-38 in the gut without affecting its plasma level, thereby possessing the potential of alleviating irinotecan-induced diarrhea without negatively impacting its therapeutic efficacy.
Role of Bacterial Translocation in the Progressive and Delayed Irinotecan Induced Diarrhea.
The goal is to facilitate a better understanding of the role of bacterial translocation in regulation of irinotecan disposition and toxicity, and the potential implications in patients.
Prophylactic effect of scopolamine butylbromide, a competitive antagonist of muscarinic acetylcholine receptor, on irinotecan-related cholinergic syndrome
It is recommended for patients receiving ≥ 150 mg/m2 irinotecan who may develop cholinergic syndrome at high frequency to prophylactically administer scopolamine butylbromide at the next scheduled treatment.
Diarrhoea in adult cancer patients: ESMO Clinical Practice Guidelines.